VironervaPharmaceutical
Proprietary Technology

The VN-Platform™
Advanced Lipid-Mediated Transport

Our proprietary platform utilizes a unique anhydrous precursor—Xylothrin™—to facilitate cross-membrane transport with unprecedented molecular fidelity.

Catalytic Isolate

Xylothrin™
Molecular Architecture

Xylothrin™ is a proprietary catalytic isolate derived from rare biogenic sources. Its unique crystalline structure enables it to act as a molecular scaffold, maintaining the structural integrity of therapeutic payloads during the critical transit phase across biological membranes.

Molecular Weight487.3 Da
Purity Grade99.8%+
Stability IndexSI-9.7
BBB AffinityKa 2.4nM
XYLOTHRIN™ 3D LATTICE MODEL
Analytical Verification

HPLC Purity Analysis
99.8%+ Compound Integrity

10080604020002468101214RETENTION TIME (MIN)Rt 7.2min | 99.83%Xylothrin™ Primary Peak
MethodRP-HPLC C18
DetectionUV 254nm
Run Time15 min
Purity99.83%
Mechanism of Action

Five-Stage Delivery
Precision Protocol

Our process ensures that critical neurological compounds remain bioavailable even under the most extreme thermodynamic conditions.

Stage 01

Anhydrous Precursor Isolation

Xylothrin™ is extracted from rare biogenic catalysts under strict moisture-free conditions, preserving its unique crystalline lattice structure.

01
Stage 02

Lipid Nanoparticle Encapsulation

The therapeutic payload is encapsulated within precision-engineered lipid nanoparticles, calibrated for optimal BBB receptor affinity.

02
Stage 03

Catalytic Stabilization

Xylothrin™ acts as a molecular scaffold, preventing denaturation during transit and maintaining bioavailability across extreme thermodynamic conditions.

03
Stage 04

Cross-Membrane Transport

Lipid-mediated transcytosis enables the stabilized compound to traverse the blood-brain barrier with high fidelity, reaching target neural tissue.

04
Stage 05

Controlled Payload Release

pH-responsive mechanisms ensure the therapeutic agent is released precisely at the neural target site, maximizing efficacy while minimizing systemic exposure.

05

Ready to explore our platform capabilities?